Patent · US Active

Inhibitors of janus kinases

US8349865B2 · kind B2 · utility

1Cited by

0References

7Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

Tony Siu · Brookline, US
Jonathan R. Young · Southborough, US
Michael D. Altman · Cambridge, US
Alan B. Northrup · Reading, US
Matthew H. Katcher · Brookline, US
Ellalahewage Sathyajith Kumarasinghe · Harvard, US
Ekaterina Kozina · Evanston, US
Scott Peterson · Woodinville, US
Matthew L. Childers · Medfield, US

Key dates

Filing date	Sep 8, 2008
Grant date	Jan 8, 2013
Priority date	—
Expiry date	Aug 26, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/14
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.